Market Overview - The A-share market is currently in a continuation phase of the upward trend since the 924 market, showing wide fluctuations. The key to breaking out of this range may lie in the upcoming policy announcements at the end of July and September [10] - The overall market sentiment remains positive, allowing for short-term opportunistic investments [10] Company Dynamics - Rongchang Biopharma (688331.SH) signed a cooperation agreement with Vor Biopharma for the licensing of its proprietary drug, Taitasip, with a total transaction value of $4.23 billion. This includes an upfront payment of $125 million and potential milestone payments of up to $4.1 billion [29][30] - Zhenghai Biopharma (300653.SZ) has obtained a Class II medical device registration certificate for its non-absorbable surgical sutures, which will enhance its product line in surgical tissue repair [31][32] - Shuanghuan Technology (007007.SZ) has received approval for a private placement to raise up to 708.96 million yuan, which will be used to acquire a 68.59% stake in Hongyi Company, supporting its business development [33][34] Industry Trends - The renewable energy sector saw a slight decrease in green certificate issuance in May, with 215 million certificates issued, a 0.59% decrease from the previous month. However, the average trading price of green certificates increased by 18.12% to 2.73 yuan per certificate [28] - The banking sector has shown resilience, benefiting from recent financial policies and increased investor interest, particularly in digital currency initiatives [9][10]